A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor
Mitchell F. Brin(AbbVie (United States)), William C. Koller(Stanford University), Seth L. Pullman(Columbia University Irving Medical Center), John T. Doucette(Icahn School of Medicine at Mount Sinai), Caroline M. Tanner(NewYork–Presbyterian Hospital), Kapil D. Sethi(Augusta University), Richard Dubinsky(Georgetown University), Joseph Y. Matsumoto(NewYork–Presbyterian Hospital), J H Friedman(NewYork–Presbyterian Hospital), John N. Caviness(Mayo Clinic), B. V. Manyam(NewYork–Presbyterian Hospital), Ali H. Rajput(John T. Mather Memorial Hospital), Kelly E. Lyons(University of Kansas Medical Center), Cynthia L. Comella(Rush University), Charles H. Adler(WinnMed)
Cited by 232
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
Variable expression of Parkinson's disease
|Neurology|1990|1.3k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein
|Nature Genetics|1997|1k